Cowen analyst Ken Cacciatore is the latest to defend Coherus Biosciences (NASDAQ: CHRS), reiterating an Outperform rating and price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Coherus Biosciences (CHRS) PT Lowered to $24 at Credit Suisse; Neulasta Biosimilar CRL Poses Greater Risk for CHS-1701June 14, 2017 9:10 AM Coherus Biosciences (CHRS) PT Lowered to $43 at BMO Capital; 'CHS-1701 CRL Disappointing but Issues Addressable - Buy on Weakness' June 12, 2017 12:03 PM Coherus Biosciences (CHRS) PT Lowered to $37 at Baird Following FDA Letter June 12, 2017 11:33 AM Coherus BioSciences (CHRS) Receives CRL from FDA for CHS-1701 BLAJune 12, 2017 6:38 AM Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)June 12, 2017 6:37 AM